Skip to main content
. 2016 Jun 21;57(1):7–32. doi: 10.1002/jcph.766

Figure 4.

Figure 4

Evolution of therapeutic monoclonal antibodies. Fully mouse antibodies developed with early hybridoma technology were highly immunogenic. Development of recombinant DNA technologies resulted in more humanized and less immunogenic antibodies: chimeric, humanized, and fully human.45, 46, 48